BRPI0512814A - exosomas imunossupressivas - Google Patents

exosomas imunossupressivas

Info

Publication number
BRPI0512814A
BRPI0512814A BRPI0512814-5A BRPI0512814A BRPI0512814A BR PI0512814 A BRPI0512814 A BR PI0512814A BR PI0512814 A BRPI0512814 A BR PI0512814A BR PI0512814 A BRPI0512814 A BR PI0512814A
Authority
BR
Brazil
Prior art keywords
exosomes
immunosuppressive
present
activity
compositions
Prior art date
Application number
BRPI0512814-5A
Other languages
English (en)
Inventor
Paul D Robbins
Seon-Hee Kim
Peter Wehling
Original Assignee
Univ Pittsburgh Of The Commmmo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Of The Commmmo filed Critical Univ Pittsburgh Of The Commmmo
Publication of BRPI0512814A publication Critical patent/BRPI0512814A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

EXOSOMAS IMUNOSSUPRESSIVAS A presente invenção refere-se a métodos e composições para uso na mediação de uma reação imunossupressiva. As composições da invenção compreendem exosomas tendo atividade imunossupressíva. Tais exosomas podem ser derivadas de uma variedade de tipos diferentes de células, incluindo células apresentadoras de antígenos como células dendríticas e macrófagos. Antes do isolamento de exosomas, às células podem ser geneticamente projetadas para expressar moléculas capazes de intensificar a atividade imunossupressiva das exosomas e/ou podem ser expostas a um ou mais agentes, corno citocinas ou inibidores de citocina, que são também capazes de intensificar a atividade imunossupressiva de exosomas. A presente invenção também se refere ao uso de tais exosomas para o tratamento de doenças e distúrbios associados à ativação indesejável do sistema imune. A presente invenção também inclui exosomas isoladas diretamente de soro que foram mostradas como sendo imunossupressivas.
BRPI0512814-5A 2004-07-01 2005-07-01 exosomas imunossupressivas BRPI0512814A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58530204P 2004-07-01 2004-07-01
PCT/US2005/023336 WO2006007529A2 (en) 2004-07-01 2005-07-01 Immunosuppressive exosomes

Publications (1)

Publication Number Publication Date
BRPI0512814A true BRPI0512814A (pt) 2008-04-08

Family

ID=35784369

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512814-5A BRPI0512814A (pt) 2004-07-01 2005-07-01 exosomas imunossupressivas

Country Status (9)

Country Link
US (1) US20060116321A1 (pt)
EP (1) EP1773381A4 (pt)
JP (1) JP2008505104A (pt)
KR (1) KR20070058441A (pt)
CN (1) CN101022824A (pt)
AU (1) AU2005262319A1 (pt)
BR (1) BRPI0512814A (pt)
CA (1) CA2572065A1 (pt)
WO (1) WO2006007529A2 (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US20060177515A1 (en) * 2005-02-09 2006-08-10 Reinhold Schmieding Method of producing autogenous or allogenic blood serum and related logistics
WO2007015174A2 (en) * 2005-07-08 2007-02-08 Exothera L.L.C. Exosome-specific ligands, their preparartion and uses
ES2461189T3 (es) 2006-01-05 2014-05-19 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
ES2736726T3 (es) * 2006-03-09 2020-01-07 Aethlon Medical Inc Eliminación extracorpórea de partículas microvesiculares
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
EP2117305A4 (en) * 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE
CA2685840C (en) * 2007-04-30 2016-12-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
ES2627059T3 (es) 2007-08-03 2017-07-26 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
AU2008310704B2 (en) * 2007-10-11 2014-03-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
US20110053157A1 (en) * 2008-02-01 2011-03-03 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US20110003008A1 (en) * 2008-02-22 2011-01-06 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles
CN102007223B (zh) * 2008-02-28 2014-06-18 俄亥俄州立大学研究基金会 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES
WO2010118979A1 (en) 2009-04-07 2010-10-21 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
BRPI0900815A2 (pt) * 2009-04-23 2010-12-28 Sociedade Benef Israelita Bras Hospital Albert Einstein método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro
KR20120037992A (ko) * 2009-07-16 2012-04-20 더 제너럴 하스피탈 코포레이션 핵산 분석
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US20130029339A1 (en) 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
EP2475372B2 (en) 2009-09-10 2020-10-21 Velin-Pharma A/S Method for the preparation of micro-rna and its therapeutic application
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found SUBSTANCES AND METHODS THAT CAN BE USED TO ACT ON THE GROWTH, MIGRATION, AND INVASION OF TUMOR CELLS
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
US20170189475A9 (en) * 2009-12-10 2017-07-06 Orthogen Ag Combination preparation comprising a cytokine antagonist and corticosteroid
US20120315324A1 (en) 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
WO2011106376A2 (en) * 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP3563858A1 (en) * 2010-10-18 2019-11-06 Agency For Science, Technology And Research Use of exosomes to promote or enhance wound healing
US20130295574A1 (en) 2010-11-10 2013-11-07 Exosome Diagnostics, Inc. Method for Isolation of Nucleic Acid Containing Particles and Extraction of Nucleic Acids Therefrom
AU2011326032B2 (en) 2010-11-12 2016-10-06 The Ohio State University Research Foundation Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
WO2012076194A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit cytokin-antagonist und corticosteroid
WO2012076193A1 (de) 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
SG183579A1 (en) * 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
ITRM20110403A1 (it) * 2011-07-28 2013-01-29 Ospedale Pediatrico Bambino Gesu Microvescicole isolate da cellule mesenchimali come agenti immunosoppressori.
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
CN104619353A (zh) * 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
DE102012019088A1 (de) 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
WO2014159662A1 (en) 2013-03-13 2014-10-02 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
PL3369435T3 (pl) * 2013-07-18 2020-04-30 Xalud Therapeutics, Inc. Kompozycja do leczenia choroby zapalnej stawów
JP6353073B2 (ja) 2013-12-20 2018-07-04 アドヴァンスド リジェン メディカル テクノロジーズ，エルエルシー 細胞回復のための組成物並びにその作製及び使用方法
US10772911B2 (en) 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
US10590384B2 (en) 2014-01-14 2020-03-17 Luterion Co., Ltd. Luterial and method for isolating and culturing the same
JP6862182B2 (ja) * 2014-01-14 2021-04-21 チョイ ウォンチョルＣＨＯＩ， Ｗｏｎ Ｃｈｅｏｌ ルテリアル、並びにその分離および培養方法
WO2016011383A1 (en) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Methods for using exosomes to monitor transplanted organ status
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN104673749B (zh) * 2015-02-12 2017-10-20 江苏大学 一种粒细胞样髓源性抑制细胞来源exosomes及其应用
KR101686064B1 (ko) * 2015-09-21 2016-12-13 (주)프로스테믹스 면역 억제 및 항염증성 조성물
WO2017080669A1 (en) * 2015-11-13 2017-05-18 Orthogen Ag Pharmaceutical preparation effective in age-related disorders
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
JP7022994B2 (ja) * 2016-03-14 2022-02-21 カプリコール，インコーポレイテッド 眼炎症および目の化学的損傷を細胞外小胞で処置する方法
CA3023468A1 (en) 2016-04-29 2017-11-02 Advanced ReGen Medical Technologies, LLC Microrna compositions and methods of making and using same
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
EP3254684B1 (en) * 2016-06-08 2019-10-23 Lysatpharma GmbH Human platelet lysate or fraction enriched in human platelet-derived extracellular vesicles, for use in medicine
EP3500285B1 (en) * 2016-08-16 2022-04-20 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
KR20190049690A (ko) * 2016-08-17 2019-05-09 오르토겐 아게 항-노화 약학 제제
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
WO2018056481A1 (ko) * 2016-09-23 2018-03-29 ㈜프로스테믹스 면역 억제 및 항염증성 조성물
US20200046766A1 (en) 2016-10-13 2020-02-13 Vbc Holdings Llc Cancer stem cell exosomes
CN110072534A (zh) 2016-10-13 2019-07-30 Vbc控股有限责任公司 外泌体的医学应用
US20200046779A1 (en) 2016-10-13 2020-02-13 Vbc Holdings Llc Anti-inflammatory exosomes from inflamed cells or tissues
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
SG10202112528QA (en) 2017-05-12 2021-12-30 Jackson Lab Nsg mice lacking mhc class i and class ii
WO2018226758A2 (en) * 2017-06-05 2018-12-13 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage
WO2019010373A1 (en) * 2017-07-06 2019-01-10 Children's National Medical Center EXOSOMES AND METHODS OF USE
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
KR101964991B1 (ko) * 2017-12-10 2019-04-02 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 포함하는 엑소좀 키트의 새로운 용도
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019143847A1 (en) 2018-01-18 2019-07-25 Advanced ReGen Medical Technologies, LLC Therapeutic compositions and methods of making and using the same
CN110604813A (zh) * 2018-06-14 2019-12-24 深圳市人民医院 一种肿瘤细胞来源外泌体抗原在dc疫苗中的应用方法
EP3613424A1 (en) 2018-08-23 2020-02-26 Orthogen AG Novel methods for the production of pharmaceutical agents
EP4112730A1 (en) * 2020-02-28 2023-01-04 National University Corporation Kanazawa University Immunoregulatory method, nucleic acid composition for immunoregulation and use thereof
WO2023081924A1 (en) * 2021-11-08 2023-05-11 Cornell University Olfactory extracellular vesicles and uses thereof
WO2023121578A1 (en) * 2021-12-24 2023-06-29 Kemal Tunc Tiryaki A method of isolating a high number of exosome extracts with high-activity from animal-derived cord blood or fetal animal or animal milk or other animal-derived fluids to allow high-activity exosome-liposome hybridization
CN114569792B (zh) * 2022-02-10 2023-01-20 北京鑫康辰医学科技发展有限公司 一种可防粘连的肌腱材料及其制备方法
CN116751745A (zh) * 2023-08-09 2023-09-15 北京圣美细胞生命科学工程研究院有限公司 一种组合免疫细胞外泌体多肽再生因子及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
AU2002325739A1 (en) * 2001-09-18 2003-04-01 Anthony E. Bolton Apoptosis-mimicking natural vesicles and use thereof in medical treatment

Also Published As

Publication number Publication date
AU2005262319A1 (en) 2006-01-19
CN101022824A (zh) 2007-08-22
WO2006007529A3 (en) 2006-08-31
KR20070058441A (ko) 2007-06-08
WO2006007529A2 (en) 2006-01-19
CA2572065A1 (en) 2006-01-19
WO2006007529A9 (en) 2006-04-27
EP1773381A2 (en) 2007-04-18
US20060116321A1 (en) 2006-06-01
JP2008505104A (ja) 2008-02-21
EP1773381A4 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
BRPI0512814A (pt) exosomas imunossupressivas
Kim et al. DNA damage and senescence in osteoprogenitors expressing Osx1 may cause their decrease with age
von Spee-Mayer et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
Chambers et al. 1α, 25‐dihydroxyvitamin D3 in combination with transforming growth factor‐β increases the frequency of Foxp3+ regulatory T cells through preferential expansion and usage of interleukin‐2
Daniel et al. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile
Carlini et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions
Kundu et al. Regulation of CYP 27 B 1 and CYP 24 A 1 hydroxylases limits cell‐autonomous activation of vitamin D in dendritic cells
Chen et al. Exosomes derived from T regulatory cells suppress CD8+ cytotoxic T lymphocyte proliferation and prolong liver allograft survival
Cho et al. Modulation of gut microbiota and delayed immunosenescence as a result of syringaresinol consumption in middle-aged mice
ECSP088751A (es) Anticuerpos contra la il-22 humana y usos para los mismos
BRPI0921799B8 (pt) compostos que expandem células-tronco hematopoétticas
BR112017018224A2 (pt) métodos para manipulação de célula t alogênica para aumentar sua persistência e/ou implante em pacientes
Hill et al. Glycogen synthase kinase‐3 controls IL‐10 expression in CD4+ effector T‐cell subsets through epigenetic modification of the IL‐10 promoter
BRPI0618486A2 (pt) uso de células progenitoras multipotentes em adultos
Aggarwal et al. Dynamics of regulatory T cells (Tregs) in patients with oral squamous cell carcinoma
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
MX2007007259A (es) Inhibidores de homodimerizacion de myd88.
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
EP3760224A3 (en) Novel combinations for antigen based therapy
PH12018502278A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
Figueroa et al. Novel approaches to lupus drug discovery using stem cell therapy. Role of mesenchymal-stem-cell-secreted factors
Bonezi et al. Flavivirus-mediating B cell differentiation into antibody-secreting cells in humans is associated with the activation of the tryptophan metabolism
Janke et al. In vitro‐induced Th17 cells fail to induce inflammation in vivo and show an impaired migration into inflamed sites
Matos et al. Physiological levels of 25‐hydroxyvitamin D3 induce a suppressive CD4+ T cell phenotype not reflected in the epigenetic landscape
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]